Get the Stockscreener App
6.50
5.69%
0.35
Liminatus Pharma Inc stock is traded at $6.50, with a volume of 5,978.
It is up +5.69% in the last 24 hours and up +0.00% over the past month.
Liminatus Pharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing cancer therapies and treatments. The GCC Vaccine of the company is in Phase II of clinical trials designed for immune behavior towards colorectal, pancreatic, gastric, and esophageal cancers that express Guanylyl Cyclase C.
See More
Previous Close:
$6.15
Open:
$6.16
24h Volume:
5,978
Relative Volume:
2.50
Market Cap:
$164.29M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+0.00%
1M Performance:
+0.00%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$6.06
$6.52
1-Week Range:
$5.50
$7.99
52-Week Range:
$5.50
$7.99
Liminatus Pharma Inc Stock (LIMN) Company Profile
Compare LIMN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LIMN
Liminatus Pharma Inc
|
6.1548 | 164.29M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
433.66 | 128.25B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
544.60 | 63.70B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
563.88 | 39.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
256.24 | 33.27B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
234.43 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Liminatus Pharma Inc Stock (LIMN) Financials Data
There is no financial data for Liminatus Pharma Inc (LIMN). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
5.73%
1.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):